Skip to content
Screener

Denali Therapeutics Inc. DNLI Other Research And Development Expense

Other Research And Development Expense at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$1.98M-36.4%
OS Therapies logo
OS TherapiesOSTX
$0—
RFL
Rafael Holdings, Inc.RFL
$22K-51.1%
CTO
Citius Oncology, Inc.CTOR
$469K-2.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%

Segments

By segment

See full
Therapeutics Segment$16.49M-33.6%

Other financials

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×